Maxygen, Inc. (Maxygen) is a biotechnology company engaged in the discovery and development of improved protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company uses the MolecularBreeding directed evolution technology platform, along with ancillary technologies. The portfolio of the product candidates includes MAXY-G34 and MAXY-4. The MAXY-G34 product candidate has been designed to be an improved pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia. The MAXY-4 product candidates are designed to be CTLA-4 Ig therapeutics for the treatment of a range of autoimmune disorders, including rheumatoid arthritis. In July 2008, the Company sold the hematology assets, including MAXY-VII, the factor VIIa program, and assets related to the factor VIII and factor IX programs, and granted certain licenses to the MolecularBreeding technology platform to Bayer HealthCare LLC.